Heron Therapeutics Inc
NASDAQ:HRTX
Heron Therapeutics Inc
Heron Therapeutics, Inc is a biotechnology company, which engages in the development of pharmaceutical products for acute care and oncology patients. The company is headquartered in San Diego, California and currently employs 302 full-time employees. The firm commercializes a portfolio of products to care for acute care and oncology patients. Its oncology care product portfolio includes SUSTOL and CINVANTI. SUSTOL is used for the prevention of acute and delayed nausea and vomiting associated with both moderately emetogenic chemotherapy (MEC), and anthracycline and cyclophosphamide (AC) combination chemotherapy regimens. CINVANTI is an intravenous (IV) formulation of aprepitant, a substance P/neurokinin-1 (NK1) receptor antagonist. Its acute care product portfolio includes ZYNRELEF (HTX-011), HTX-019, and HTX-034. HTX-011 is a dual-acting local anaesthetic that delivers a fixed-dose combination of the local anaesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam. HTX-019 is an investigational agent for the prevention of postoperative nausea and vomiting. HTX-034 is a product candidate for postoperative pain management.
Heron Therapeutics, Inc is a biotechnology company, which engages in the development of pharmaceutical products for acute care and oncology patients. The company is headquartered in San Diego, California and currently employs 302 full-time employees. The firm commercializes a portfolio of products to care for acute care and oncology patients. Its oncology care product portfolio includes SUSTOL and CINVANTI. SUSTOL is used for the prevention of acute and delayed nausea and vomiting associated with both moderately emetogenic chemotherapy (MEC), and anthracycline and cyclophosphamide (AC) combination chemotherapy regimens. CINVANTI is an intravenous (IV) formulation of aprepitant, a substance P/neurokinin-1 (NK1) receptor antagonist. Its acute care product portfolio includes ZYNRELEF (HTX-011), HTX-019, and HTX-034. HTX-011 is a dual-acting local anaesthetic that delivers a fixed-dose combination of the local anaesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam. HTX-019 is an investigational agent for the prevention of postoperative nausea and vomiting. HTX-034 is a product candidate for postoperative pain management.
Financing Completed: Heron successfully completed long-awaited financing, removing a major company overhang and enabling full focus on commercial execution.
Revenue Growth: Net revenue reached $38.2 million for Q3, with strong performance from flagship products ZYNRELEF, APONVIE, and CINVANTI.
ZYNRELEF & APONVIE Momentum: ZYNRELEF sales rose 49% year-over-year, and APONVIE sales jumped 173% year-over-year, with both products gaining significant traction in acute care.
J-Code Milestone: ZYNRELEF secured a permanent product-specific J-code effective October 1, streamlining reimbursement and expected to boost adoption.
Gross Margin Impact: Gross margin slightly declined to 68.8% due to a one-time inventory write-off, but adjusted gross margin remains stable around 74.5%.
Oncology Franchise: CINVANTI remains steady despite competitive pressures, while SUSTOL faces ongoing declines and will be wound down in 2026 with potential reintroduction in 2027.
Guidance Reaffirmed: Management reaffirmed full-year 2025 net revenue guidance of $153 million to $163 million and adjusted EBITDA of $9 million to $13 million.
